{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.15","value":"4.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"title":"Week 4: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"74.6","value":"55.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"title":"Week 4: 1 hour postdose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"147","value":"94.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"title":"Week 4: 2 hours postdose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"115","value":"89.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"title":"Week 4: 4 hours postdose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"62.3","value":"50.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"title":"Week 4: 6 hours postdose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Plasma concentrations of ibrutinib were reported.","dispersionType":"Standard Deviation","groups":[{"description":"Treatment naive or relapsed/refractory Waldenstrom's Macroglobulinemia (WM) Japanese participants received ibrutinib 420 milligrams (mg) (3\\*140 mg capsules) orally, once daily, from Day 1 of Week 1 until disease progression or unacceptable toxicity along with rituximab 375 milligrams per square meter (mg/m\\^2) intravenously (IV) weekly for 4 consecutive weeks (Day 1 of Weeks 1 to 4), followed by a second course of once-weekly rituximab for 4 consecutive weeks (from Week 17 to 20) after a 12-week interval.","id":"OG000","title":"Ibrutinib + Rituximab"}],"paramType":"MEAN","populationDescription":"The Pharmacokinetic (PK) evaluable analysis set included all enrolled participants who had received at least 1 dose of ibrutinib and had at least 1 post-dose PK sample. Here, n (number analyzed) refers to number of participants evaluable for specified timepoints.","reportingStatus":"POSTED","timeFrame":"Day 1 of Week 4: Predose, 1 hour, 2 hours, 4 hours, and 6 hours postdose","title":"Plasma Concentrations of Ibrutinib","type":"SECONDARY","unitOfMeasure":"nanograms per milliliter (ng/mL)"}